Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Drug insight: Clopidogrel nonresponsiveness.

Gurbel PA, Tantry US.

Nat Clin Pract Cardiovasc Med. 2006 Jul;3(7):387-95. Review.

PMID:
16810174
2.

Clopidogrel resistance?

Gurbel PA, Tantry US.

Thromb Res. 2007;120(3):311-21. Epub 2006 Nov 14. Review.

PMID:
17109936
3.

Clinical applications of antiplatelet therapy.

Wiviott SD, Tantry US, Gurbel PA; American College of Cardiology; American Heart Association.

Rev Cardiovasc Med. 2006 Summer;7(3):130-46; quiz 148-9. Review.

PMID:
17088858
4.

Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.

Thromb Res. 2009 May;124(1):46-51. doi: 10.1016/j.thromres.2008.10.007. Epub 2008 Nov 28.

PMID:
19041120
5.

[Clopidogrel resistance].

Güray Y, Güray U, Korkmaz S.

Anadolu Kardiyol Derg. 2009 Jun;9(3):231-7. Review. Turkish.

6.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
7.

Optimal antiplatelet treatment for percutaneous coronary intervention: clopidogrel vs. ticlopidine.

Almsherqi ZA, McLachlan CS, Mossop P, Deng Y.

Int J Cardiol. 2007 Jan 2;114(1):101-2. Epub 2005 Dec 15.

PMID:
16343664
8.

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.

J Am Coll Cardiol. 2007 Feb 13;49(6):657-66. Epub 2007 Jan 26.

9.

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA.

J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16. Epub 2007 Mar 26. Review.

11.

Clopidogrel resistance--the cardiologist's perspective.

Fefer P, Hod H, Matetzky S.

Platelets. 2007 May;18(3):175-81. Review.

PMID:
17497429
12.

Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence.

Tourmousoglou CE, Rokkas CK.

Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):312-22. Review.

PMID:
18855644
13.

Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.

Gurbel PA, Antonino MJ, Tantry US.

Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):989-1004. doi: 10.1517/17425250903107772. Review.

PMID:
19575629
14.

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV.

Am Heart J. 2007 Aug;154(2):221-31. Review.

PMID:
17643570
15.

Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.

Am J Cardiol. 2009 Oct 15;104(8):1078-82. doi: 10.1016/j.amjcard.2009.06.007.

PMID:
19801028
16.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
17.

Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.

Bonello L, De Labriolle A, Scheinowitz M, Lemesle G, Roy P, Steinberg DH, Pinto Slottow TL, Pakala R, Pichard AD, Barragan P, Camoin-Jau L, Dignat-George F, Paganelli F, Waksman R.

Heart. 2009 Aug;95(15):1214-9. doi: 10.1136/hrt.2008.152660. Epub 2009 Feb 5. Review.

PMID:
19196732
18.

Role of clopidogrel in managing atherothrombotic cardiovascular disease.

Eshaghian S, Kaul S, Amin S, Shah PK, Diamond GA.

Ann Intern Med. 2007 Mar 20;146(6):434-41. Review.

PMID:
17371888
19.

Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

Steinhubl S, Roe MT.

Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. Review. Erratum in: Cardiovasc Drug Rev. 2007 Autumn;25(3):299.

PMID:
17614940
20.

Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.

Ben-Dor I, Kleiman NS, Lev E.

Am J Cardiol. 2009 Jul 15;104(2):227-33. doi: 10.1016/j.amjcard.2009.03.022. Epub 2009 May 13. Review.

PMID:
19576352

Supplemental Content

Support Center